



Clinical trial results:

A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to assess efficacy and safety of the herbal medicinal product Sinupret extract coated tablets in patients with chronic rhinosinusitis

Summary

EudraCT number	2015-001952-31
Trial protocol	DE
Global end of trial date	23 August 2017

Results information

Result version number	v1 (current)
This version publication date	06 January 2023
First version publication date	06 January 2023

Trial information

Trial identification

Sponsor protocol code	CRS-03
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bionorica SE
Sponsor organisation address	Kerschensteinerstraße 11-15, Neumarkt, Germany, 92318
Public contact	Head of cooperate communication, Bionorica SE, info@bionorica.de
Scientific contact	Head of Research and Development, Bionorica SE, research.development@bionorica.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 June 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 August 2017
Global end of trial reached?	Yes
Global end of trial date	23 August 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of the herbal medicinal product Sinupret extract versus placebo in the treatment of chronic rhinosinusitis (CRS) in adults.

Protection of trial subjects:

This study was conducted in compliance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice, including the archiving of essential documents.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 April 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 363
Country: Number of subjects enrolled	Germany: 209
Worldwide total number of subjects	572
EEA total number of subjects	572

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	489
From 65 to 84 years	83
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 624 patients were enrolled; of these, 51 were not randomized and not treated. In total, 573 (91.8% of the enrolled population) patients were randomized, of whom 1 patient was not treated. In total, 285 patients were randomized to treatment with Sinupret extract (test IMP) and 287 patients to treatment with placebo.

Pre-assignment

Screening details:

The trial consists of a screening phase of up to 2 weeks (V1 to V2). Patients were required to have CRS symptoms for more than 52 weeks prior to enrolment, diagnosis of CRS confirmed by an ENT-specialist, and severe symptoms at screening and baseline (MSS of at least 10 points).

Period 1

Period 1 title	Period 1 (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo coated tablets

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

One tablet placebo three times a day.

Arm title	Sinupret extract
------------------	------------------

Arm description:

Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid.

Arm type	Experimental
Investigational medicinal product name	Sinupret extract
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid for 16 weeks.

Number of subjects in period 1	Placebo	Sinupret extract
Started	287	285
End of treatment	259	257
End of observation	255	252
Completed	255	252
Not completed	32	33
Adverse event, serious fatal	1	-
Consent withdrawn by subject	11	6
Extreme CRS-related pain symptomatology	2	3
Reasons not related to disease	1	1
Adverse event, non-fatal	11	10
Pregnancy	-	1
Non-compliance with study drug	1	2
Lost to follow-up	4	4
Progressive disease	1	4
Protocol deviation	-	2

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Placebo coated tablets	
Reporting group title	Sinupret extract
Reporting group description: Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid.	

Reporting group values	Placebo	Sinupret extract	Total
Number of subjects	287	285	572
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	244	245	489
From 65-84 years	43	40	83
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	46.4	45.9	-
standard deviation	± 14.73	± 14.06	-
Gender categorical			
Units: Subjects			
Female	168	164	332
Male	119	121	240

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo coated tablets	
Reporting group title	Sinupret extract
Reporting group description:	
Sinupret extract coated tablet containing 160 mg native dry extract; 1 tablet tid.	
Subject analysis set title	Sinupret extract - FAS
Subject analysis set type	Full analysis
Subject analysis set description:	
All randomized patients with at least one documented application of IMP and with at least one observed post-baseline value for the primary efficacy variable (MSSINV).	
Subject analysis set title	Placebo - FAS
Subject analysis set type	Full analysis
Subject analysis set description:	
All randomized patients with at least one documented application of IMP and with at least one observed post-baseline value for the primary efficacy variable (MSSINV).	
Subject analysis set title	Sinupret extract - SAF
Subject analysis set type	Safety analysis
Subject analysis set description:	
All patients who received at least one dose of trial medication; patients who were treated with more than one type of clinical trial medication by mistake were analyzed according to the clinical trial medication they received the longest.	
Subject analysis set title	Placebo - SAF
Subject analysis set type	Safety analysis
Subject analysis set description:	
All patients who received at least one dose of trial medication; patients who were treated with more than one type of clinical trial medication by mistake were analyzed according to the clinical trial medication they received the longest.	
Subject analysis set title	Sinupret extract - PPS
Subject analysis set type	Per protocol
Subject analysis set description:	
All patients from the FAS without major protocol deviations.	
Subject analysis set title	Placebo - PPS
Subject analysis set type	Per protocol
Subject analysis set description:	
All patients from the FAS without major protocol deviations.	

Primary: MSS-INV

End point title	MSS-INV
End point description:	
The primary efficacy endpoint was the MSS-INV at V7.	
End point type	Primary
End point timeframe:	
After 12 weeks of treatment (Visit 7).	

End point values	Sinupret extract - FAS	Placebo - FAS		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	279	283		
Units: Score points				
arithmetic mean (standard deviation)	5.4 (\pm 3.34)	5.6 (\pm 3.69)		

Statistical analyses

Statistical analysis title	Van Elteren test adjusted for centre
Comparison groups	Sinupret extract - FAS v Placebo - FAS
Number of subjects included in analysis	562
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3192
Method	Van Elteren test
Parameter estimate	Mean difference (final values)
Point estimate	-0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.73
upper limit	0.45

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All AEs occurring between V2 (randomisation) and V8 (end of observation) are reported.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.0

Reporting groups

Reporting group title	Sinupret extract
-----------------------	------------------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Sinupret extract	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 285 (1.05%)	5 / 287 (1.74%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events	0	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Parathyroid tumour benign			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Transient ischaemic attack			
alternative assessment type: Non-systematic			

subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Meniere's disease			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Psychiatric disorders			
Adjustment disorder with depressed mood			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			

Hyperparathyroidism alternative assessment type: Non-systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 285 (0.00%) 0 / 0 0 / 0	1 / 287 (0.35%) 0 / 1 0 / 0	
Musculoskeletal and connective tissue disorders Pathological fracture alternative assessment type: Non-systematic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 285 (0.00%) 0 / 0 0 / 0	1 / 287 (0.35%) 0 / 1 0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Sinupret extract	Placebo	
Total subjects affected by non-serious adverse events subjects affected / exposed	113 / 285 (39.65%)	116 / 287 (40.42%)	
Vascular disorders Circulatory collapse alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 2	
Hypertension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Hypotension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Thrombosis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Surgical and medical procedures			

Dental operation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Tooth extraction alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
General disorders and administration site conditions Asthenia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	1 / 287 (0.35%) 1	
Fatigue alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Malaise alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Mucosal dryness alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Oedema peripheral alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Pyrexia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	2 / 287 (0.70%) 2	
Reproductive system and breast disorders			

Menstrual disorder alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Vulvovaginal inflammation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Cough alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	3 / 285 (1.05%) 3	4 / 287 (1.39%) 4	
Dysphonia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	2 / 287 (0.70%) 2	
Dyspnoea alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Epistaxis alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	2 / 285 (0.70%) 2	1 / 287 (0.35%) 1	
Nasal congestion alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Nasal obstruction alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	1 / 287 (0.35%) 1	
Noninfective bronchitis alternative assessment type: Non-			

systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Oropharyngeal pain		
alternative assessment type: Non-systematic		
subjects affected / exposed	6 / 285 (2.11%)	6 / 287 (2.09%)
occurrences (all)	6	7
Pharyngeal inflammation		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	2 / 287 (0.70%)
occurrences (all)	1	2
Pharyngeal oedema		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Pleurisy		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Rhinalgia		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Rhinorrhoea		
alternative assessment type: Non-systematic		
subjects affected / exposed	3 / 285 (1.05%)	3 / 287 (1.05%)
occurrences (all)	3	3
Throat irritation		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Upper respiratory tract inflammation		
alternative assessment type: Non-systematic		

subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Psychiatric disorders Insomnia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Product issues Device failure alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Investigations Alanine aminotransferase increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	1 / 287 (0.35%) 1	
Blood alkaline phosphatase increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Blood creatine increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Blood glucose increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Blood urea increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Body temperature decreased alternative assessment type: Non-systematic			

subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
C-reactive protein increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	2 / 287 (0.70%)
occurrences (all)	0	2
Eosinophil count increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)
occurrences (all)	1	1
Gamma-glutamyltransferase increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	3 / 285 (1.05%)	2 / 287 (0.70%)
occurrences (all)	3	2
Haemoglobin decreased		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Hepatic enzyme increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Lymphocyte count increased		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Neutrophil count decreased		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Injury, poisoning and procedural complications		
Bone contusion		
alternative assessment type: Non-systematic		

subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Concussion		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Contusion		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 285 (0.70%)	0 / 287 (0.00%)
occurrences (all)	2	0
Fall		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Hand fracture		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Humerus fracture		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Ligament sprain		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 285 (0.70%)	2 / 287 (0.70%)
occurrences (all)	2	2
Muscle injury		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Muscle strain		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1

Nail injury alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Tendon rupture alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Thermal burn alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Tooth fracture alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Cardiac disorders Atrial fibrillation alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Nervous system disorders Dizziness alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Dysgeusia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Headache alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	21 / 285 (7.37%) 27	14 / 287 (4.88%) 17	
Migraine			

alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 285 (0.70%)	1 / 287 (0.35%)	
occurrences (all)	3	4	
Paraesthesia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Radiculopathy			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Sciatica			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)	
occurrences (all)	1	1	
Sensory disturbance			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Somnolence			
alternative assessment type: Non-systematic			
subjects affected / exposed	3 / 285 (1.05%)	1 / 287 (0.35%)	
occurrences (all)	4	1	
Tension headache			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Trigeminal neuralgia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	2	
Blood and lymphatic system disorders			
Microcytic anaemia			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Neutropenia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Thrombocytopenia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Thrombocytosis			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Ear and labyrinth disorders			
Ear congestion			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Ear discomfort			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 285 (0.70%)	1 / 287 (0.35%)	
occurrences (all)	2	1	
Ear pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	2 / 285 (0.70%)	1 / 287 (0.35%)	
occurrences (all)	2	1	
Tinnitus			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Vertigo			
alternative assessment type: Non-systematic			

subjects affected / exposed occurrences (all)	2 / 285 (0.70%) 3	1 / 287 (0.35%) 1	
Eye disorders Eye pain alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 3	
Ocular hyperaemia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Gastrointestinal disorders Abdominal discomfort alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	0 / 285 (0.00%) 0	1 / 287 (0.35%) 1	
Abdominal distension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Abdominal pain alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	4 / 287 (1.39%) 5	
Abdominal pain upper alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	5 / 285 (1.75%) 5	6 / 287 (2.09%) 6	
Breath odour alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 285 (0.35%) 1	0 / 287 (0.00%) 0	
Colitis alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Diarrhoea		
alternative assessment type: Non-systematic		
subjects affected / exposed	8 / 285 (2.81%)	8 / 287 (2.79%)
occurrences (all)	9	9
Diverticulum intestinal		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Dry mouth		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Dyspepsia		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 285 (0.70%)	3 / 287 (1.05%)
occurrences (all)	2	3
Dysphagia		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Flatulence		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	2 / 287 (0.70%)
occurrences (all)	0	2
Food poisoning		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 285 (0.70%)	1 / 287 (0.35%)
occurrences (all)	2	1
Gastric disorder		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0

Gastritis		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Gastrointestinal disorder		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Gastrointestinal inflammation		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Gastrooesophageal reflux disease		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)
occurrences (all)	1	1
Haematochezia		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Lip swelling		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Nausea		
alternative assessment type: Non-systematic		
subjects affected / exposed	4 / 285 (1.40%)	0 / 287 (0.00%)
occurrences (all)	4	0
Toothache		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Vomiting		
alternative assessment type: Non-systematic		

subjects affected / exposed	4 / 285 (1.40%)	0 / 287 (0.00%)
occurrences (all)	4	0
Skin and subcutaneous tissue disorders		
Dermatitis allergic		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Erythema		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Hyperhidrosis		
alternative assessment type: Non-systematic		
subjects affected / exposed	8 / 285 (2.81%)	0 / 287 (0.00%)
occurrences (all)	8	0
Pruritus		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	2 / 287 (0.70%)
occurrences (all)	1	2
Psoriasis		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Rash		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)
occurrences (all)	1	1
Rash papular		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Rash pruritic		
alternative assessment type: Non-systematic		

subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Skin hypopigmentation			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Skin odour abnormal			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Urticaria			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Haematuria			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)	
occurrences (all)	1	1	
Nephrolithiasis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)	
occurrences (all)	1	1	
Urine odour abnormal			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Back pain			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	2 / 287 (0.70%)	
occurrences (all)	0	2	
Musculoskeletal stiffness			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	2 / 287 (0.70%)	
occurrences (all)	0	2	
Spinal pain			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)	
occurrences (all)	1	1	
Infections and infestations			
Acute sinusitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	2 / 287 (0.70%)	
occurrences (all)	1	2	
Bronchitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	3 / 285 (1.05%)	2 / 287 (0.70%)	
occurrences (all)	3	2	
Bronchitis viral			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Conjunctivitis			
alternative assessment type: Non-systematic			

subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Cystitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	3 / 285 (1.05%)	4 / 287 (1.39%)
occurrences (all)	3	4
Gastroenteritis		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Gastroenteritis viral		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Gastrointestinal infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Haemophilus infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Herpes zoster		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Influenza		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1

Laryngitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Nasal herpes		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Oral herpes		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	2 / 287 (0.70%)
occurrences (all)	1	2
Pharyngitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	5 / 287 (1.74%)
occurrences (all)	0	6
Pneumonia		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)
occurrences (all)	1	1
Respiratory tract infection viral		
alternative assessment type: Non-systematic		
subjects affected / exposed	2 / 285 (0.70%)	0 / 287 (0.00%)
occurrences (all)	2	0
Rotavirus infection		
alternative assessment type: Non-systematic		
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)
occurrences (all)	0	1
Sinusitis		
alternative assessment type: Non-systematic		
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)
occurrences (all)	1	0
Skin infection		
alternative assessment type: Non-systematic		

subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Soft tissue infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Tonsillitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	6 / 285 (2.11%)	4 / 287 (1.39%)	
occurrences (all)	7	4	
Urinary tract infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	3 / 285 (1.05%)	0 / 287 (0.00%)	
occurrences (all)	3	0	
Viral infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	1 / 287 (0.35%)	
occurrences (all)	1	1	
Viral pharyngitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Viral upper respiratory tract infection			
alternative assessment type: Non-systematic			
subjects affected / exposed	29 / 285 (10.18%)	32 / 287 (11.15%)	
occurrences (all)	30	35	
Metabolism and nutrition disorders			
Fluid imbalance			
alternative assessment type: Non-systematic			

subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Hypercholesterolaemia			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 285 (0.00%)	1 / 287 (0.35%)	
occurrences (all)	0	1	
Lactose intolerance			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 285 (0.35%)	0 / 287 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported